Conjugates that include separable connectives

ES3073782T3Undetermined Publication Date: 2026-07-15ASTRAZENECA AB
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
ES · ES
Patent Type
Patents
Current Assignee / Owner
ASTRAZENECA AB
Filing Date
2024-08-14
Publication Date
2026-07-15

AI Technical Summary

Technical Problem

There is a need for antibody drug conjugates with β-glucuronidase-cleavable linkers that can selectively deliver a drug to a biological target with favorable physicochemical properties, including solubility and lipophilicity, to address the non-favorable side effects of microtubule inhibitor therapy in cancer treatment.

Method used

Conjugates comprising a microtubule inhibitor linked through a β-glucuronidase-cleavable linker, which undergo slower enzymatic cleavage, improving stability, solubility, and reducing off-target toxicity, making them suitable for cancer treatment.

Benefits of technology

The conjugates exhibit improved efficacy and tolerability by reducing the release of free drug in off-target tissues, enhancing stability and solubility, and providing a favorable toxicity profile.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000057_0000
    Figure 00000057_0000
  • Figure 00000057_0001
    Figure 00000057_0001
  • Figure 00000058_0000
    Figure 00000058_0000
Patent Text Reader

Abstract

The specification refers to conjugates comprising a linker of formula (IMA): and their pharmaceutically acceptable salts. The specification also refers to the use of the conjugates for the treatment of diseases such as cancer, as they are useful intermediates for their synthesis.
Need to check novelty before this filing date? Find Prior Art